ILSUNG IS CO., LTD.

003120· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩20,100-0.50%

2026-08-04

Financials

Valuation Metrics

ILSUNG IS CO., LTD.'s Market Cap is ₩2673B. At end of 2025 it was ₩2899B. Ranked #684 of 2,436 in KR market (top 28%), #404 of 787 on KOSPI (top 51%), #78 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 33%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	267.33B KRW	KR#684/2,436 Sec#78/234
Revenue	64.38B KRW	KR#1,647/2,436 Sec#109/234
Net Income	1.20B KRW	KR#1,418/2,436 Sec#97/234
Total Assets	402.93B KRW	KR#845/2,436 Sec#51/234
Net Assets	378.93B KRW	KR#598/2,436 Sec#40/234
Employees	200	KR#1,099/2,436 Sec#91/234
Value
P/E	221.96x	KR#1,473/2,436 Sec#100/234
P/B	0.71x	KR#1,152/2,436 Sec#63/234
PEG	88.55x	KR#846/2,436 Sec#59/234
P/S	4.15x	KR#2,101/2,436 Sec#137/234
FCF Yield	0.65%	KR#1,166/2,436 Sec#86/234
Profitability
ROE	0.32%	KR#1,475/2,436 Sec#102/234
ROA	0.30%	KR#1,445/2,436 Sec#102/234
Op. Margin	-8.76%	KR#1,953/2,436 Sec#132/234
Revenue Growth	0.53%	KR#1,411/2,436 Sec#133/234
Earnings Growth	2.51%	KR#882/2,436 Sec#58/234
Financial Health
Debt Ratio	106.33%	KR#371/2,436 Sec#52/234
Total Debt	0 KRW	KR—/2,436 Sec—/234
FCF	1.75B KRW	KR#1,099/2,436 Sec#79/234
Cash	120.17B KRW	KR#409/2,436 Sec#18/234
Current Ratio	12.24x	KR#70/2,436 Sec#19/234
Dividend
Div. Yield	5.94%	KR#181/2,436 Sec#5/234
Div. Growth	20.00%	KR#423/2,436 Sec#22/234
Performance
1Y Return	-16.94%	KR#1,168/2,436 Sec#89/234
1M Return	1.11%	KR#778/2,436 Sec#71/234
From 52W High	-31.40%	KR#452/2,436 Sec#30/234
1Y MDD	-36.13%	KR#382/2,436 Sec#27/234
Trading
Volume	4,898 shares	KR#2,268/2,436 Sec#223/234
Foreign Own.	0.29%	KR—/2,436 Sec—/234
Per Share
EPS	91 KRW	KR#1,373/2,436 Sec#96/234
BPS	52,907 KRW	KR#227/2,436 Sec#16/234

Company Info

CEO 윤석근, 엄대식, 윤종호(각자대표)

Employees 200

Founded 1961

HQ 서울특별시 용산구, KR

Website www.ilsungis.com

동사는 1954년 설립되어 1961년 일성신약으로 공식 출범하고 1985년 거래소시장에 상장됨. 글락소스미스클라인(GSK)과 협력해 항생제 분야를 특화하여 세계적 수준의 페니실린 항생제를 생산 중이며, 오구멘틴은 13,366백만원 매출을 기록하고 일본 등 해외에 수출하고 있음. 인간존중 사상을 바탕으로 건강한 삶을 위해 의약품 연구개발에 노력하고, 국내외 대학과 산학협력을 통한 공동 연구를 진행하고 있음. 일성아이에스는 1961년에 설립되었으며 서울특별시 용산구에 본사를 두고 있습니다.